Merus N.V. (MRUS)
Dec 30, 2025 - MRUS was delisted (reason: acquired by GMAB)
81.00
-0.50 (-0.61%)
Inactive · Last trade price on Dec 16, 2025
Merus Employees
As of December 31, 2024, Merus had 321 total employees, including 260 full-time and 61 part-time employees. The number of employees increased by 92 or 40.17% compared to the previous year.
Employees
321
Change (1Y)
92
Growth (1Y)
40.17%
Revenue / Employee
$176,343
Profits / Employee
-$1,187,336
Market Cap
n/a
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 321 | 92 | 40.17% | 260 | 61 |
| Dec 31, 2023 | 229 | 8 | 3.62% | 172 | 57 |
| Dec 31, 2022 | 221 | 80 | 56.74% | 164 | 57 |
| Dec 31, 2020 | 141 | 9 | 6.82% | 93 | 48 |
| Dec 31, 2019 | 132 | 34 | 34.69% | 87 | 45 |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
MRUS News
- 6 weeks ago - Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period - Business Wire
- 2 months ago - Bicara Therapeutics: Intriguing Opportunity Given Rival Merus' $8B Buyout - Seeking Alpha
- 2 months ago - Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab - PRNewsWire
- 3 months ago - 3 Investable Laggards In An Overbought Market - Seeking Alpha
- 3 months ago - Merus' Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety - GlobeNewsWire
- 3 months ago - Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS - Business Wire
- 3 months ago - Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V. - GlobeNewsWire
- 3 months ago - Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire